Kylee J. Wible Ph.D.

Kylee J. Wible PhD, BCMAS serves as the US Medical Director for Hematology/Oncology Medical Affairs at Ipsen since January 2023, where responsibilities include developing and executing the medical strategy for tazemetostat in hematologic malignancies and rare solid tumors, as well as leading real-world evidence studies utilizing Flatiron datasets. Previously, at Epizyme from April 2020 to January 2023, Kylee held the position of Associate Medical Director, Oncology/Hematology and played a crucial role in launching tazemetostat for relapsed/refractory follicular lymphoma, engaging with key opinion leaders in the field. Prior to this, Kylee conducted significant research at MD Anderson Cancer Center as a Postdoctoral Research Fellow, focusing on arginine methyltransferases in various cancers and identifying biomarkers for DLBCL. Academic training includes a Ph.D. in Genetics and a B.Sc. in Zoology from Texas A&M University.